title: Practical implications for the administration of 13-cis retinoic acid in pediatric oncology.
abstract: Children with high-risk neuroblastoma are treated with polychemotherapy, surgery, radiotherapy and even autologous stem-cell transplantation. On top of this complex treatment, most children also receive 13-cis retinoic acid as differentiation agent. As no suitable pharmaceutical formulation is available so far, there are often problems with the administration of the product in children. The present report describes some practical recommendations for the administration of isotretinoin in children treated for high-risk neuroblastoma.
authors.affiliation: Department of Pediatric Hemato-Oncology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. tiene.bauters@uzgent.be
authors.forename: Tiene G M
authors.initials: TG
authors.lastname: Bauters
authors.forename: Geneviève
authors.initials: G
authors.lastname: Laureys
authors.forename: Véronique
authors.initials: V
authors.lastname: Van de Velde
authors.forename: Yves
authors.initials: Y
authors.lastname: Benoit
authors.forename: Hugo
authors.initials: H
authors.lastname: Robays
mesh_terms: D000284:Administration, Oral; D002648:Child; D003679:Deglutition / Q000502:physiology; D004750:Enteral Nutrition / Q000009:adverse effects / Q000379:methods; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D008495:Medical Oncology / Q000379:methods*; D009447:Neuroblastoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D015474:Isotretinoin